Cargando…

Association between atherosclerosis and Alzheimer's disease: A systematic review and meta‐analysis

BACKGROUND: To evaluate the relationship between atherosclerosis and Alzheimer's disease (AD), we conducted a systematic review and meta‐analysis to study the difference of carotid intima–media thickness (CIMT) and the prevalence of atherosclerosis between AD patients and non‐AD controls. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Beijia, Shi, Xinrui, Xing, Yi, Tang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177569/
https://www.ncbi.nlm.nih.gov/pubmed/32162494
http://dx.doi.org/10.1002/brb3.1601
Descripción
Sumario:BACKGROUND: To evaluate the relationship between atherosclerosis and Alzheimer's disease (AD), we conducted a systematic review and meta‐analysis to study the difference of carotid intima–media thickness (CIMT) and the prevalence of atherosclerosis between AD patients and non‐AD controls. METHODS: The studies on the association between atherosclerosis and AD were manually searched in PubMed, Embase, Cochrane Library, and CNKI (China National Knowledge Infrastructure) spanned to September 2018 according to PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines. RESULTS: Thirteen studies were included in the final analysis, seven studies with data on the mean CIMT (610 cases and 417 controls) and ten studies reporting on the prevalence of atherosclerosis (1,698 cases and 6,452 controls). Compared with controls, AD group showed a significantly higher CIMT (overall standard mean difference = 0.94; 95% CI, 0.48–1.40; p < .0001) and an increased prevalence of atherosclerosis (OR = 1.46; 95% CI, 1.26–1.68; p < .0001). CONCLUSIONS: Atherosclerosis is significantly associated with AD. CIMT might be a useful marker to predict the risk of AD and assess the vascular burden. The finding is also important for possible prevention and treatment of AD in the future.